Polypeptide antibiotic 26a from Bacillus subtilis. IV. Evaluation of biological in vivo activity.
The studies performed with the antibiotic 26a, which has a close resemblance to bacitracin family polypeptide antibiotics, revealed a prominent therapeutic and protective actions. The antibiotic is characterized by a moderately low toxicity, lack of cytotoxic and cytostatic effects on several tissue cultures, and therapeutic effectiveness in lethal streptococcal infections in mice, and corynebacterial infections in guinea pigs.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000633:toxicity; D001412:Bacillus subtilis; D001426:Bacterial Proteins / Q000494:pharmacology* / Q000633:toxicity; D003353:Corynebacterium diphtheriae / Q000187:drug effects; D004165:Diphtheria / Q000517:prevention & control; D006168:Guinea Pigs; D051379:Mice; D010455:Peptides / Q000494:pharmacology* / Q000633:toxicity; D013290:Streptococcal Infections / Q000517:prevention & control; D013297:Streptococcus pyogenes / Q000187:drug effects
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D010455:Peptides